<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We investigated the protective effect of subchronic treatment of the A2A receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, SCH 58261 (0.01 mg/kg, i.p.), administered 5 min, 6 h and 15 h after permanent right middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAo) </plain></SENT>
<SENT sid="1" pm="."><plain>Twenty-four hours after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, an extensive <z:mp ids='MP_0003717'>pallid</z:mp> area, evaluated by <z:chebi fb="0" ids="52815">cresyl violet</z:chebi> staining, is evident in the vascular territories supplied by the <z:chebi fb="70" ids="34342">MCA</z:chebi>, the striatum and the sensory motor cortex </plain></SENT>
<SENT sid="2" pm="."><plain>The <z:mp ids='MP_0003717'>pallid</z:mp> area reflects the extent of necrotic neurons </plain></SENT>
<SENT sid="3" pm="."><plain>Soon after waking, rats showed a definite contralateral turning behavior which was significantly reduced by SCH 58261 treatment </plain></SENT>
<SENT sid="4" pm="."><plain>Twenty-four hours after MCAo, SCH 58261 significantly improved the neurological deficit and reduced ischemic damage in the striatum and cortex </plain></SENT>
<SENT sid="5" pm="."><plain>Phospho-p38 <z:chebi fb="0" ids="52290">mitogen</z:chebi>-activated protein kinase (MAPK), evaluated by Western Blot, increased by 500% in the ischemic striatum 24 h after MCAo </plain></SENT>
<SENT sid="6" pm="."><plain>SCH 58261 treatment significantly reduced phospho-p38 MAPK by 70% </plain></SENT>
<SENT sid="7" pm="."><plain>Microglia was immunostained using the OX-42 antibody </plain></SENT>
<SENT sid="8" pm="."><plain>Phospho-p38 MAPK and OX-42-immunoreactive cells are localized in the ventral striatum and frontoparietal cortex </plain></SENT>
<SENT sid="9" pm="."><plain>Furthermore, both OX-42 and phospho-p38 MAPK-immunoreactive cells have overlapping morphological features, typical of reactive microglia </plain></SENT>
<SENT sid="10" pm="."><plain>SCH 58261 reduced phospho-p38 MAPK immunoreactivity in the striatum and in the cortex without changing the microglial cell <z:mp ids='MP_0000002'>morphology</z:mp> </plain></SENT>
<SENT sid="11" pm="."><plain>These results indicate that the protective effect of the <z:chebi fb="3" ids="16335">adenosine</z:chebi> <z:chebi fb="68" ids="48706">antagonist</z:chebi> SCH 58261 during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> is not due to reduced microglial activation but involves inhibition of phospho-p38 MAPK and suggest that treatment with the A2A <z:chebi fb="68" ids="48706">antagonist</z:chebi> from the first hour to several hours after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> may be a useful therapeutic approach in <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
</text></document>